TitleNCI first International Workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on the biological considerations of hematological relapse following allogeneic stem c
Publication TypeJournal Article
Year of Publication2010
AuthorsCairo, Mitchell S., Jordan Craig T., Maley Carlo C., Chao Clifford, Melnick Ari, Armstrong Scott A., Shlomchik Warren, Molldrem Jeff, Ferrone Soldano, Mackall Crystal, Zitvogel Laurence, Bishop Michael R., Giralt Sergio A., and June Carl H.
JournalBiol Blood Marrow Transplant
Date Published2010 Jun
KeywordsBiomedical Research, Drug Resistance, Neoplasm, Epigenesis, Genetic, Gene Expression Regulation, Neoplastic, Graft vs Tumor Effect, Hematologic Neoplasms, Hematopoietic Stem Cell Transplantation, Humans, Neoplastic Stem Cells, Radiation Tolerance, Secondary Prevention, Transplantation, Homologous

<p>Hematopoietic malignant relapse still remains the major cause of death following allogeneic hematopoietic stem cell transplantation (HSCT). Although there has been a large focus on the immunologic mechanisms responsible for the graft-versus-tumor (GVT) effect or lack thereof, there has been little attention paid to investigating the biologic basis of hematologic malignant disease relapse following allogeneic HSCT. There are a large number of factors that are responsible for the biologic resistance of hematopoietic tumors following allogeneic HSCT. We have focused on 5 major areas including clonal evolution of cancer drug resistance, cancer radiation resistance, genomic basis of leukemia resistance, cancer epigenetics, and resistant leukemia stem cells. We recommend increased funding to pursue 3 broad areas that will significantly enhance our understanding of the biologic basis of malignant relapse after allogeneic HSCT, including: (1) genomic and epigenetic alterations, (2) cancer stem cell biology, and (3) clonal cancer drug and radiation resistance.</p>

Alternate JournalBiol Blood Marrow Transplant
PubMed ID20227509
PubMed Central IDPMC3711411
Grant ListR01 CA138188 / CA / NCI NIH HHS / United States
R01 CA110249 / CA / NCI NIH HHS / United States
U10 CA098543-08 / CA / NCI NIH HHS / United States
P01 CA109688 / CA / NCI NIH HHS / United States
U10 CA098543 / CA / NCI NIH HHS / United States